Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax: 2014-2024

Historic Long-Term Deferred Tax for Ani Pharmaceuticals (ANIP) over the last 11 years, with Dec 2024 value amounting to $85.1 million.

  • Ani Pharmaceuticals' Long-Term Deferred Tax rose 5.52% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 5.52%. This contributed to the annual value of $85.1 million for FY2024, which is 6.18% down from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Long-Term Deferred Tax is $85.1 million, which was down 6.18% from $90.7 million recorded in FY2023.
  • Ani Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $90.7 million during FY2023, with a 5-year trough of $51.7 million in FY2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Long-Term Deferred Tax value was $85.1 million (recorded in 2024), while the average stood at $85.7 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Long-Term Deferred Tax spiked by 34.91% in 2020, and later dropped by 6.18% in 2024.
  • Ani Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $51.7 million in 2020, then spiked by 31.39% to $67.9 million in 2021, then increased by 19.76% to $81.4 million in 2022, then increased by 11.49% to $90.7 million in 2023, then decreased by 6.18% to $85.1 million in 2024.